Skip to main content

EU vaccine row, MNB asset purchases, CBRT impresses

The risk of a large shortfall in COVID-19 vaccine deliveries to the EU threatens to delay the recovery that we had expected in Emerging Europe during the first half of this year. While the central bank of Hungary kept its main policy rates on hold this week, we think its decision to step up its asset purchase programme will be followed with a cut to short-term interest rates in the coming months. Finally, the Turkish central bank’s Inflation Report provided a (rare) realistic assessment of the outlook and offers further evidence that the shift to orthodoxy will stick.

Become a client to read more

This is premium content that requires an active Capital Economics subscription to view.

Already have an account?

You may already have access to this premium content as part of a paid subscription.

Sign in to read the content in full or get details of how you can access it

Register for free

Sign up for a free account to:

  • Unlock additional content
  • Register for Capital Economics events
  • Receive email updates and economist-curated newsletters
  • Request a free trial of our services


Get access